Press coverage about Onconova Therapeutics (NASDAQ:ONTX) has been trending somewhat positive on Wednesday, Accern Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Onconova Therapeutics earned a coverage optimism score of 0.22 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.1065716770066 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Onconova Therapeutics, Inc. (NASDAQ:ONTX) – Market Cap Secrets – Nasdaq Journal (nasdaqjournal.com)
- Low Wild stock to watch: Onconova Therapeutics, Inc. (ONTX) – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Oversold Signal Stock: Onconova Therapeutics, Inc. (ONTX) – Nasdaq Chronicle (nasdaqchronicle.com)
- Onconova Therapeutics, Inc. (ONTX) locked -39.89% below … – The Stocks News (press release) (thestocksnews.com)
- Onconova Therapeutics to Present Data on a First-in-class Dual Inhibitor of CDK4/6 + ARK5 at the American … – GlobeNewswire (press release) (globenewswire.com)
ONTX has been the subject of several recent analyst reports. HC Wainwright set a $6.00 price objective on shares of Onconova Therapeutics and gave the stock a “buy” rating in a research report on Thursday, January 4th. Maxim Group restated a “hold” rating on shares of Onconova Therapeutics in a research report on Friday, March 2nd. ValuEngine raised shares of Onconova Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 14th. Finally, Zacks Investment Research lowered shares of Onconova Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, December 12th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $8.00.
Onconova Therapeutics (NASDAQ:ONTX) last announced its earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.10. The company had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.31 million. Onconova Therapeutics had a negative net margin of 3,061.37% and a negative return on equity of 558.97%. analysts predict that Onconova Therapeutics will post -1.41 earnings per share for the current fiscal year.
In related news, major shareholder 683 Capital Management, Llc bought 200,000 shares of the stock in a transaction on Thursday, February 8th. The stock was bought at an average price of $1.04 per share, with a total value of $208,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 13.30% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Onconova Therapeutics (NASDAQ:ONTX) Getting Somewhat Favorable News Coverage, Study Shows” was originally reported by BBNS and is owned by of BBNS. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://baseballnewssource.com/2018/03/21/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-onconova-therapeutics-ontx-stock-price/1967686.html.
Onconova Therapeutics Company Profile
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.
Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.